Datavault AI Inc. (NASDAQ: DVLT) has expanded its definitive licensing agreement with DataMeds AI Inc. (NASDAQ: MEDS) to extend its PharmacyChain blockchain-related technology beyond pharmaceutical distribution into commercial healthcare, healthspan and wellness applications. The expanded relationship is designed to support patient-controlled health data access, monetization and real-world asset tokenization across pharmacy, medical, laboratory and wearable device environments, leveraging a behavioral healthcare patent portfolio focused on medical logistics, IoT population health and AI-driven remote patient monitoring.
Under the amended agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally contemplated for tax optimization purposes. The companies said the agreement accelerates deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models. For more details, see the full press release at https://ibn.fm/vBAxH.
Datavault AI (NASDAQ: DVLT) is leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions. Datavault AI’s Acoustic Sciences division features WiSA, ADIO and Sumerian patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The Company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai.
The implications of this announcement are significant for the healthcare industry, as it introduces a model where patients can control and monetize their own health data, potentially transforming how medical information is shared and utilized. By extending blockchain technology into commercial healthcare, Datavault AI and DataMEDS are positioning themselves at the forefront of a trend toward data sovereignty and real-world asset tokenization. This could lead to new revenue streams for patients and healthcare providers, while also improving data security and interoperability across different systems, from pharmacies to wearable devices. The behavioral healthcare patent portfolio underpinning this initiative suggests a focus on mental health and chronic disease management, areas ripe for innovation with AI-driven remote monitoring. As the global health and wellness market continues to expand, this partnership could accelerate the adoption of decentralized, patient-centric data models, challenging traditional healthcare data management practices.
